Acelity's innovative negative-pressure wound therapy
system changes the game by enhancing delivery of four therapies on
a single device
SANTA CLARA, California,
Sept. 15, 2017 /PRNewswire/ -- Based
on its recent analysis of the negative-pressure wound therapy
(NPWT) market, Frost & Sullivan recognizes Acelity with the
2017 North American Negative-Pressure Wound Therapy Product
Leadership Award for its two new therapies: V.A.C.ULTA™ 4
Therapy System, which incorporates a fifth-generation software
upgrade that provides delivery of four therapies on a single
device, allowing physicians to treat various wounds with a single
system, and V.A.C. VERAFLO CLEANSE CHOICE™ Dressing, which
provides clinicians with a novel, adjunctive non-surgical option
that may help clean large complex wounds when complete surgical
debridement is not possible or appropriate.
Photo:
http://mma.prnewswire.com/media/550424/Aceilty_Award.jpg
Healthcare economies, such as the
United States (US), are faced with shifting challenges,
including rising operational costs at hospitals, staffing
constraints, and cost burdens carried by care facilities for
hospital-acquired infections. While US healthcare policies, along
with value-based reimbursement models, are a clinical and economic
driver in the wound care market, the need exists for wound care
companies to integrate their treatment modalities into new care
models that better track and manage chronic wounds across various
care settings due to the shift from pay-for-service models to
pay-for-performance and quality-of-care based payment models. The
current chronic wound care market is also significantly fragmented
because of the many ways a typical wound can be treated, including
active healing dressings, advanced passive dressings, other unique
energy- or mechanical-based solutions, and negative-pressure wound
treatment systems (NPWT), including vacuum assisted-closure
(V.A.C.®) therapy.
"Acelity is a leading provider of advanced wound care
solutions," said Patrick Riley,
Principal Analyst at Frost & Sullivan. "The company pioneered
NPWT, and its advanced V.A.C. VERAFLO™ Therapy combines the
benefits of V.A.C.® Therapy and automated topical wound solution
distribution and removal to help heal and prepare the wound for
closure quickly and effectively. The new V.A.C.ULTA™ 4 Therapy
System sets the benchmark with its capability to delivery four
therapies through a single device."
The four therapies include:
- V.A.C. VERAFLO™ Therapy with Instillation, which automates
alternating cycles of wound cleansing with a topical solution and
V.A.C.® Therapy, allowing for wound cleansing and therapy to
maintain a closed environment to enhance healing. V.A.C. VERAFLO™
Therapy is poised to become the new gold standard of NPWT, as
studies have reported patient outcomes better than the current gold
standard V.A.C.® Therapy.
- Traditional V.A.C.® Therapy
- ABTHERA™ Open Abdomen Negative Pressure Therapy, which provides
negative-pressure therapy for temporary abdominal closure to help
reduce edema and fluid, empowering primary fascial closure.
- PREVENA™ Negative Pressure Incision Management Therapy, which
provides NPWT therapy for closed incisions after a surgical
procedure.
Furthermore, all four therapies utilize Acelity's advanced
SENSAT.R.A.C.™ Technology with EASYCLEAR PURGE™ which employs
advanced software and algorithms in addition to multi-lumen
technology that work together to monitor and regulate the set
pressure continuously at the wound site, as well as helping reduce
blockages. Acelity's recently launched V.A.C. VERAFLO CLEANSE
CHOICE™ dressing for use with V.A.C. VERAFLO™ Therapy helps loosen,
solubilize, detach, and remove viscous wound exudate without
surgical intervention, effectively preparing the wound for
closure.
"Acelity's software upgrade has also improved the ease-of-use
factor for the V.A.C.ULTA™ 4 Therapy System," said Riley. "Acelity
has designed the interface to be similar to a mobile phone, with
applications (apps) corresponding to each therapy for easy
selection; thus, reducing the number of steps needed for therapy
delivery."
Acelity conducts hands-on training for clinicians, as well as
transitioning training for customers moving to the new V.A.C.ULTA™
4 Therapy System. The company also maintains customer, technical
and clinical support teams that are committed to providing detailed
support to customers for administrative questions, technological
troubleshooting, and can give guidance on use of Acelity's
products.
Acelity also recently launched V.A.C. VERAFLO CLEANSE CHOICE™
Dressing. When used with V.A.C. VERAFLO™ Therapy, Acelity's
negative pressure wound therapy and instillation (NPWTi-d) system,
the dressing may provide rapid cleansing of wounds with the goal of
augmenting the healing environment. The novel therapeutic dressing
facilitates removal of thick wound exudate when surgical
debridement is not possible or delayed, and offers prompt
adjunctive wound cleansing for complex wounds.
In addition, Acelity has led the way in the next frontier of
NPWT with its digital health offerings. iOn RESULTS™
Remote Therapy Monitoring works in conjunction with the V.A.C.ULTA™
Therapy System to monitor the therapy units' performance in the
hospital setting. iOn PROGRESS™ Remote Therapy Monitoring delivers
the first continuous monitoring and ready intervention for patients
receiving negative pressure wound therapy in the home.
Due to Acelity's commitment to improve patient outcomes through
continuous technological innovation and outstanding customer
support, Acelity has earned Frost & Sullivan's 2017 North
American Negative-Pressure Wound Therapy Product Leadership
Award.
Each year, Frost & Sullivan presents this award to the
company that has developed a product with innovative features and
functionality that is gaining rapid market acceptance. The award
recognizes the quality of the solution and the customer value
enhancements it enables.
Frost & Sullivan Best Practices awards recognize companies
in a variety of regional and global markets for demonstrating
outstanding achievement and superior performance in areas such as
leadership, technological innovation, customer service, and
strategic product development. Industry analysts compare market
participants and measure performance through in-depth interviews,
analysis, and extensive secondary research to identify best
practices in the industry.
About Acelity
Acelity L.P. Inc. and its subsidiaries are a global advanced
wound care company that leverages the strengths of Kinetic
Concepts, Inc. and Systagenix Wound Management, Limited. Available
in more than 90 countries, the innovative and complementary
ACELITY™ product portfolio delivers value through solutions that
speed healing and lead the industry in quality, safety and customer
experience. Headquartered in San Antonio,
Texas, Acelity employs nearly 5,000 people around the
world.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in
collaboration with clients to leverage visionary innovation that
addresses the global challenges and related growth opportunities
that will make or break today's market participants. For more than
50 years, we have been developing growth strategies for the global
1000, emerging businesses, the public sector and the investment
community. Contact us: Start the discussion.
Contact:
Estefany Ariza
P: 210.477.8469
F: 210.348.1003
E: Estefany.Ariza@frost.com